TimeTeller’s saliva test aims to align cancer treatment with patients’ internal clocks

TimeTeller’s saliva test aims to align cancer treatment with patients’ internal clocks

Lead – According to TechCrunch, German health‑tech startup TimeTeller has launched a direct‑to‑consumer saliva test that measures an individual’s circadian rhythm, with the long‑term goal of timing cancer therapies to each patient’s internal clock. The company, led by physicist‑engineer and molecular biologist Angela Relógio, announced the product at TechCrunch Disrupt in San Francisco and has already secured a reimbursement partnership with Techniker Krankenkasse, one of Germany’s largest health insurers.

Founder background and motivation

As reported by TechCrunch, Angela Relógio—whose surname means “clock” in Portuguese—spent several years conducting research in oncology, circadian biology, and systems medicine at German institutions before leaving academia to create TimeTeller. Relógio’s scientific work, the article notes, focused on the observation that many cancer patients altered or discontinued treatment because of side‑effects. She described the experience as “impossible to watch” and hypothesized that when a treatment is administered could be as important as what is administered.

The test and its intended use

According to TechCrunch, TimeTeller’s core product is a saliva‑based kit that determines a user’s circadian phase. The company states that the test is not designed to provide treatment timing recommendations directly to consumers. Instead, Relógio cautioned that “that is something that we need to calculate for every single medicine; we do that in the context of clinical studies.” The article emphasizes that the current consumer kit therefore serves as a data‑collection tool rather than a stand‑alone therapeutic guide.

Market demand and early adopters

Based on reports, TimeTeller began accepting direct orders after receiving interest from longevity clinics that focus on healthy aging. These clinics reportedly view individual circadian data as a basis for personalized advice on sleep, nutrition, light exposure, and physical activity. The source further indicates that the test could have applications beyond oncology, including metabolic diseases such as diabetes, neurodegenerative conditions like Alzheimer’s, performance optimization, and women’s health. Nonetheless, the article stresses that cancer remains the startup’s core mission.

Academic origins and institutional support

According to TechCrunch, TimeTeller spun out of Berlin’s Charité university hospital before relocating to Medical School Hamburg. The move, the article explains, provided the startup with access to patients, funding, and a “fallback” employment arrangement for its team of 10 should the company be unable to meet payroll. This safety net, the source notes, has not yet been required.

Partnerships and reimbursement model

As reported by TechCrunch, TimeTeller secured a partnership with Techniker Krankenkasse, a major German health insurer. The initial arrangement involved a reimbursement scheme in which the insurer covered the cost of the test for a subset of cancer patients. Relógio indicated that both parties are now preparing to expand the reimbursement to a larger portion of the insurer’s 12 million members.

Public presentation and future vision

According to TechCrunch, Relógio presented TimeTeller onstage at TechCrunch Disrupt in San Francisco, part of the event’s Startup Battlefield competition. During the appearance, she articulated a broader ambition: to make the question “when” a central component of precision medicine, because “almost every process in our body is timed.” The article suggests that the company sees its test as a stepping stone toward more granular timing of therapies, beyond the simple classification of individuals as “morning people” or “night owls.”

Brief analysis (opinion)

The positioning of circadian timing within personalized oncology reflects a growing scientific consensus that biological rhythms influence drug metabolism and toxicity. While TimeTeller’s consumer kit currently functions primarily as a data‑gathering device, the partnership with a major insurer could accelerate clinical validation and integration into treatment protocols. However, the company’s own warnings about the need for medicine‑specific calculations underscore the complexity of translating circadian metrics into actionable clinical decisions.

Conclusion

In summary, TimeTeller’s saliva test represents an early effort to bring circadian biology into the realm of personalized cancer care. Backed by a founder with a strong research pedigree, an academic spin‑out structure, and a reimbursement partnership with Techniker Krankenkasse, the startup is positioning itself to collect the data required for future clinical studies. As the company expands its reach, the broader health‑tech community will be watching to see whether timing‑based insights can indeed improve treatment tolerability and outcomes.

Source: TechCrunch

Frequently Asked Questions

What does TimeTeller’s test measure?**

According to TechCrunch, the test analyzes a saliva sample to determine an individual’s circadian rhythm. **Q: Is the test intended to prescribe treatment timing for cancer patients?** A: As reported by TechCrunch, the direct‑to‑consumer kit does not provide treatment timing recommendations; such calculations are performed within clinical studies. **Q: Which insurer is partnering with TimeTeller for test reimbursement?** A: According to TechCrunch, the partnership is with Techniker Krankenkasse, which initially reimbursed the test for a subset of cancer patients and plans to expand coverage.

Source: TechCrunch — Read more

💚 Related Articles